Get started

Biotechnology

OCGN back to basicsOCGN kind of treading water for now. I think what we need to see are some rock-solid results from COVAXIN, which this rolling submission could be helpful in identifying. The Phase 3 results were interesting. With more warnings coming out about the current SOC EAU vaccines, another option might not be "too late" at this point. But a lot will clearly come down to the results. For now, speculation is probably playing a bigger role as we don't know much more beyond what Ocugen announced this week. Regardless, looking at chart levels, a quick Fib retracement shows a few "pain points" on the chart, namely the 618 fib that has been a frequent resistance level over the last few months. "On July 2nd, Ocugen reported new evidence from Bharat Biotech. The company shared positive results of its Phase 3 study of COVAXIN™; a whole virion inactivated COVID-19 vaccine candidate. According to the company, it demonstrated a vaccine efficacy in mild, moderate, and severe COVID-19 disease of 77.8% with efficacy against severe COVID-19 disease alone of 93.4%. “With the Delta variant becoming a dominant strain of COVID-19 in the United States, we believe that the Phase 3 efficacy results reported by Bharat Biotech demonstrate that COVAXIN™ has the potential to become an important option to expand protection against this emerging variant. Combining these data with the only Delta-variant results from a controlled Phase 3 clinical trial, evidence continues to support a favorable benefit-risk profile for COVAXIN™.” - Dr. Bruce Forrest, Acting Chief Medical Officer and a member of the vaccine scientific advisory board of Ocugen. " Quote Source: 7 Penny Stocks For Your Watch List This Week If You Like Biotech In July
NASDAQ:OCGN
by PennyStocks101
Familiar T/A on ITRM Well, doesn't this look familiar? ITRM tested is previous level of support AND resistance in a wide channel today. IDK what the sell-off was but I'm guessing the re-entry had something to do with speculation on the FDA data set to come out next month. "At the end of May, Iterum provided an update on its New Drug Application with the U.S. Food and Drug Administration. Currently, the NDA is still under review by the FDA, and the PDUFA goal date is July 25th, 2021. Since the application review for Sulopenem is on track at the moment, ITRM stock is performing well as a result. ITRM stock price has nearly doubled in the last month." Not sure if it gets the approvals necessary but "buy the rumor" might be playing a role here. Quote Source: Top 9 Penny Stocks With High Volume to Watch Right Now
NASDAQ:ITRM
by PennyStocks101
2
Here We Go (Again?) With ATOSThis is familiar territory with ATOS . Not only is there a very clear and significant support level on the chart, there's also a multi-year level of resistance the ATOS is sitting at right now. The biggest question is Now What? " Earlier this month, Atossa revealed data from a Phase 2 Endoxifen study in breast cancer. It met primary and secondary endpoints. The Phase 2 study was conducted on behalf of Atossa by Avance Clinical, a leading Australian CRO. Based on the results, the company also discussed its plan to apply to the FDA for approval to begin a clinical study in the US 'as soon as possible.' With meaningful results and potential for more clinical trials in the US, ATOS could be on the list of biotech penny stocks on Robinhood to watch this summer ." Quote Source: 7 Penny Stocks On Robinhood To Watch In June 2021
NASDAQ:ATOS
by PennyStocks101
13
Black Diamond Therapeutics Inc 🧙Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under pipeline are BDTX-189 and BDTX-1535. If you want not to miss ideas like this one,🎯 subscribe and press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
NASDAQ:BDTXLong
by yura_trades
This looks...Familiar on ATOSThis is a very interesting level for ATOS right now. The last two times before this most recent instance the stock failed to break through and hold this level. It was able to do that briefly this year but unsustainable. After consolidating this last time around, what's the catalyst to actually spark a firm move? I think a lot will come down to the next steps for AT-301 to be honest: "Recently ATOS has received phase 2 initiation approval from the Swedish Medical Product Agency for its oral Endoxifen. This drug targets mammographic breast density (MBD), to reduce and eradicate potential tumors. MBD affects millions worldwide and can reduce the effectiveness of mammograms...Doctors around the world depend on mammogram studies to detect cancer through breast density. With a drug such as Endoxifen, it would increase the ability for earlier diagnosis, which in turn could reduce breast cancer incidence... This is a large breakthrough for the company and considering the incidence of breast cancer around the world, Endoxifen could be a big deal moving forward. Investors should stay up to date with any news regarding this compound, as it is Atossa’s flagship product. However, it does have a sizable pipeline that includes a Covid-19 nasal spray treatment known as AT-301." Quote Source: 4 Top Biotech Penny Stocks To Watch In The Second Half Of June 2021
NASDAQ:ATOS
by PennyStocks101
Ionis Pharmaceuticals Inc 🧙Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy. Ionis subsequently brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). If you want not to miss ideas like this one,🎯 subscribe and press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
NASDAQ:IONSLong
by yura_trades
ONTX Onconova Therapeutics good results = good growthThere’s no reason in the world that a biopharmaceutical company like $ONTX that operates cancer research and has a very good quarterly should be stationary at the same price, rather lower than the time at which the quarterly report was submitted, which was excellent and above the expectations of the analyses. After a vertical takeoff he retracted his full price going, at present, to position himself about a 15% below. In addition, there has been a reverse split of stocks that reduces the number of shares outstanding, so the value of each individual share should increase significantly. The advisor Marketmiracle has in fact emitted a signal LONG on the Stock to the price of 6,64 usd with a target of 622 usd that is a vertical takeoff of 9268% identifying a massive entry of capitals and of interest LONG on the Stock from some great investor. Let’s just stay grounded and figure it out on the graph. The graph tells us that surely the title has the ability to climb without virtually obstacles to the resistance indicated, we see them further signs and we will reason whether the great climb should continue or not. A greater interest in biotechs and pharmaceuticals that for some time had been put aside gives us more reason to believe that the increase in price can actually take place ( see related ideas ) This idea is based on the signal generated by the Marketmiracle advisor whose link you can find by scrolling at the bottom of this page.
OLong
by MarketMiracleAdvisor
7
Bionano Genomics completes head shoulders and then up ?Bionano is a hyper-technological industry that operates at the level of the human genome. It has developed a platform with an unprecedented ability to detect structural variations in DNA molecules, is active in research for the fight against cancer and other genetic diseases. It presented excellent results days ago and now a category of big investors has started to direct its capital on it , typical feature in this period where many biotech and pharmaceutical companies seem to receive large inflows of capital ( see related ideas ) The advisor Marketmiracle tells us that thanks to the indicator Mmiracle Viewer decomposes the market to identify the positions on the securities of the various investors. It generated an input signal on Bionano Genomics at a price of 7.16 usd with a target of 15.08 usd with a potential profit of 110 %. From the fundamental point of view the company does not shine but it is a characteristic typical of all the companies that operate in the fields in which the investment in search is a necessary and determining part for the own business. I checked the situation in the chart and it seems that the target can actually be reached after a short accumulation phase that could lead the title to the formation of a bullish head shoulders, the high volatility of the stock could then help to reach such an ambitious target. Will Bionano Genomics succeed in its intent ? stay tuned.... This idea is based on the signal generated by the Marketmiracle advisor whose link you can find by scrolling at the bottom of this page.
NASDAQ:BNGOLong
by MarketMiracleAdvisor
2
I imagine this... probably ... and it’s just the beginning.According to the indicator at the base of the advisor Marketmiracle the CLVS stock is accumulating capitals and is ready for an explosion. Clovis Oncology is one of the best-selling low-cost titles but produces a drug capable of improving the lives of cancer patients worldwide. Clearly the money devoted to biotech and pharmaceutical companies during the covid period was directed to vaccine manufacturers but now, that the clouds are clearing up and the covid danger seems to have drifted away, it seems to be heading back to what are the possible cures for the diseases of the century, namely cancer, This is also demonstrated by the recent rise in prices of $AHT, which is a cancer care company ( see related idea) I imagine a movement of the title as the one indicated in the graph, but I have the feeling that it will only be the beginning, the company a few years ago priced much but much more and its trails are successful as demonstrated by the recent results. Investing in a society like this is also a way to help medicine and the entire human race.. I did a search on the fundamental analysis sites that I use as a reference and it seems according to their analysts that the current price of Clovis Oncology is absolutely below the right value, which is given around 50 USD i.imgur.com I certainly put a chip on Clovis ... I think it’s a great opportunity. Scrolling at the bottom of this page you will find the advisor Market Miracle who gave a few days ago the input signal on $CLVS.
CLong
by MarketMiracleAdvisor
5
Mirati Therapeutics good news. The price will start to rise soonI spent about 3 hours researching this company and I will divide my work into 3 parts. Last report, other positive news, and why you shouldn't open long position right now. Enjoy reading. 1) Mirati Therapeutics Reports First Quarter 2021 Financial Results (May 06, 2021) The most important information: - Initiated potentially registration-enabling trials evaluating our investigational KRASG12C inhibitor, adagrasib, in lung and colorectal cancers, as monotherapy and with other agents - POSITIVE NEWS - Plan to file an Investigational New Drug (IND) application in 2022 for our investigational KRASG12D inhibitor, MRTX1133 - POSITIVE NEWS - Presented preclinical data at AACR 2021 on an investigational synthetic lethal methylthioadenosine (MTA) cooperative PRMT5 inhibitor - POSITIVE NEWS - Research and development expenses for the first quarter of 2021 were $104.1 million, compared to $71.7 million for the same period in 2020. !!!!!!!!!! - IMPORTANT 2) Other positive news (Jun 01, 2021) - Mirati Therapeutics and Zai Lab Enter Into a Collaboration to Develop and Commercialize Adagrasib in Greater China - Mirati to receive an upfront payment of $65 million, up to approximately $273 million in potential milestone payments and high-teen- to low-twenties-percent tiered royalties 3) Why you shouldn't open long position right now First, there are too many resistance lines at the moment. I doubt that the price will suddenly rise now and break through all resistance lines. After the May report, the price did not break the white resistance line. Most likely, the next report will raise the price and in my opinion, there is a good chance that it will end the bear market this year.
MLong
by UnknownUnicorn15216778
AbCellera Biologics Inc 🧙AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes, and analyzes antibody responses to engineer new antibody drug candidates for its partners. If you want not to miss ideas like this one,🎯 subscribe and press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
NASDAQ:ABCLLong
by yura_trades
Protara Therapeutics Inc 🧙Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with rare and specialty diseases. The Protara team prioritizes creativity, diverse perspectives and tenacity to expedite our goal of bringing life-changing therapies to people with limited treatment options. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD). If you want not to miss ideas like this one,🎯 subscribe and press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
NASDAQ:TARALong
by yura_trades
2
Atreca Inc - It's time to load up. 🧙Atreca Inc is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. The company's product candidate, ATRC-101, is a monoclonal antibody in preclinical development with a novel mechanism of action and target-derived from an antibody identified using its discovery platform. -20% If you want not to miss ideas like this one,🎯 subscribe and press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
BLong
by yura_trades
2
If good for Bill Gates good for us 🧙Atreca Inc is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. The company's product candidate, ATRC-101, is a monoclonal antibody in preclinical development with a novel mechanism of action and target-derived from an antibody identified using its discovery platform. If you want more trading ideas like this one ,🎯 press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
BLong
by yura_trades
1
ACADIA Pharmaceuticals Inc 🧙Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology. If you want more trading ideas like this one ,🎯 press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
NASDAQ:ACADLong
by yura_trades
2
$BCTX PT 4-4.50BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.
NASDAQ:BCTXLong
by UnknownUnicorn19246015